Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q2 2021 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2020 Net Income-$534.76K-$534.76KN/M vs Q2 2020 EPS Diluted$0.00$0.00N/M vs Q2 2020 Operating Income-$667,869N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
derived
ended Feb 28, 2021 · filed Apr 14, 2021 · 45 d after period end